News - Genzyme

Filter

Current filters:

Genzyme

Popular Filters

26 to 50 of 70 results

Growing US uptake of Genzyme's Aubagio at three months post-launch

07-03-2013

Some 34% of surveyed US neurologists have prescribed French drug major Sanofi (Euronext: SAN) subsidiary…

AubagioBiotechnologyGenzymeMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSanofi

Genzyme's eliglustat meets endpoints in Ph III studies for Gaucher disease

18-02-2013

US biotech firm Genzyme, a subsidiary if French drug major Sanofi (Euronext: SAN) has released positive…

BiotechnologyeliglustatGenzymePharmaceuticalRare diseasesResearchSanofi

FDA clears Sanofi and Isis' Kynamro for inherited cholesterol disorder

30-01-2013

The US Food and Drug Administration yesterday approved Sanofi (Euronext: SAN) subsidiary Genzyme's orphan…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Genzyme says Lemtrada sBLA for MS accepted by FDA; reports on Aubagio

28-01-2013

French drug major Sanofi (Euronext: SAN) US biotech subsidiary Genzyme says that the US Food and Drug…

AubagioBiotechnologyGenzymeLemtradaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Sanofi MS drug Aubagio gets second approval, in Australia

21-11-2012

Having already gained approval in the largest global pharma market, the USA, French drug major Sanofi's…

Asia-PacificAubagioBiotechnologyGenzymeNeurologicalPharmaceuticalRegulationSanofi

Alnylam gets upfront $22.5 million in RNAi link with Genzyme

23-10-2012

French drug major Sanofi's (Euronext: SAN) US biotech subsidiary Genzyme has entered into an exclusive…

Alnylam PharmaceuticalsAsia-PacificBiotechnologyGenzymeLicensingPharmaceuticalRare diseasesSanofi

FDA advisory panel votes 9 to 6 to approve Genzyme's Kynamro

19-10-2012

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory yesterday voted by…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Highlights from ECTRIMS include new data for Gilenya, Sativex and Aubagio

14-10-2012

New data presented at the 28th congress of the European Committee for Treatment and Research in Multiple…

AlmirallAubagioBiotechnologyGenzymeGilenyaGW PharmaceuticalsNeurologicalNovartisPharmaceuticalResearchSanofiSativex

Osiris regains worldwide rights to Prochymal and Chondrogen from Sanofi

30-09-2012

As a result of the termination of its collaboration with Genzyme, a subsidiary of French drug major Sanofi…

BiotechnologyChondrogenGenzymeImmunologicalsInflammatory diseasesLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

FDA thumbs up for Sanofi's MS drug Aubagio

13-09-2012

As has been largely expected, the US Food and Drug Administration yesterday approved marketing of French…

AubagioBiotechnologyGenzymeNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Impax Labs settles with Genzyme over Renvela and Renagel generics

05-09-2012

USA-based Impax Laboratories (Nasdaq: IPXL) says it has reached agreement with French drug major Sanofi's…

GenzymeImpax LaboratoriesPatentsPharmaceuticalRenagelRenvelaSanofi

FDA calls on Genzyme to re-file Lemtrada sBLA

28-08-2012

French drug major Sanofi (Euronext: SAN) revealed yesterday that its US biotech subsidiary has received…

BayerBiotechnologyGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Sanofi moves on Lemtrada; Novartis Indian patent case

21-08-2012

French drug major Sanofi's (Euronext: SAN) USA-based rare diseases subsidiary Genzyme is pulling leukemia…

Asia-PacificCampathEuropeGenzymeGlivecLegalLemtradaMarkets & MarketingNorth AmericaNovartisPatentsPharmaceuticalSanofi

Sanofi 2nd-qtr hit by Plavix competition but group sales still up 6%

27-07-2012

French pharma major Sanofi (Euronext: SAN) reported second-quarter 2012 financial results with net sales…

BiotechnologyFinancialGenzymePharmaceuticalSanofi

Genzyme files multiple sclerosis drug Lemtrada with FDA and EMA

12-06-2012

French drug major Sanofi (Euronext: SAN) subsidiary Genzyme revealed this morning that it has submitted…

BayerBiotechnologyEuropeGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Sanofi's Aubagio reduces MS relapse; firm aims to build diabetes portfolio

01-06-2012

Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) today reported top-line results from…

AubagioBiotechnologyDiabetesGenzymeMergers & AcquisitionsNeurologicalPharmaceuticalResearchSanofiteriflunomide

Isis earns $25 million milestone from Genzyme as US FDA accepts Kynamro NDA

31-05-2012

The US Food and Drug Administration has accepted for filing the New Drug Application for Kynamro (mipomersen…

BiotechnologyCardio-vascularFinancialGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRegulationSanofi

Elelyso: a new therapeutic option for patients with Gaucher disease

09-05-2012

The US Food and Drug Administration recently approved Protalix BioTherapeutic's (NYSE-AMEX: OLX) Elelyso…

CerezymeElelysoGenzymeMarkets & MarketingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesShireVpriv

Genzyme gains FDA and EMA approval for Irish production plant

03-05-2012

US biotech firm Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) said yesterday that…

BiotechnologyEuropeGenzymeLumizymeMyozymeRegulationSanofi

Sanofi's strong 1st-qtr driven by Genzyme

27-04-2012

French drug major Sanofi (Euronext: SAN) posted a strong set of first-quarter 2012 financial results…

BiotechnologyFinancialGenzymePharmaceuticalSanofi

26 to 50 of 70 results

Back to top